Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)

Taiwan · Delayed Price · Currency is TWD

102.50

-2.00 (-1.91%)

Aug 19, 2026, 1:30 PM CST

TPE:6919 Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	29.39	38.04	44.43	38.93	12.82	12.34
Revenue Growth	-34.44%	-14.40%	14.13%	203.68%	3.90%	19.22%
Gross Profit	20.66	26.52	30.76	27.47	9.61	9.23
Operating Income	-831.08	-707.22	-717.14	-513.47	-319.62	-230.73
Net Income	-257.81	-351.92	-588.83	-488.46	-286.16	-224.29
Earnings Per Share	-0.17	-0.23	-0.41	-0.39	-0.24	-0.24
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	4,047	4,860	9,669	3,712	1,111	594.91
Total Debt	107.95	3	11.87	20.46	28.68	36.78
Net Cash (Debt)	3,939	4,857	9,657	3,691	1,083	558.13
Net Cash Growth	-58.06%	-49.70%	161.63%	240.96%	93.96%	-
Net Cash Per Share	2.54	3.15	6.75	2.98	0.92	0.61

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-280.99	-425.9	-522.31	-423.94	-242.76	-110.7
Capital Expenditures	-19.37	-16.53	-10	-8.6	-14.16	-14.9
Free Cash Flow	-300.36	-442.43	-532.31	-432.54	-256.93	-125.6
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	70.30%	69.72%	69.23%	70.56%	74.94%	74.83%
Operating Margin	-2827.47%	-1859.31%	-1613.95%	-1318.88%	-2493.17%	-1869.95%
Pretax Margin	-877.11%	-925.20%	-1325.18%	-1254.64%	-2232.10%	-1817.52%
Profit Margin	-877.11%	-925.20%	-1325.18%	-1254.64%	-2232.10%	-1817.76%
FCF Margin	-1021.87%	-1163.16%	-1197.97%	-1111.01%	-2004.12%	-1017.90%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 19, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	27.04	64.85	-	-	-	-
PS Ratio	5529.86	6316.21	2123.71	604.64	587.23	-